Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab

被引：2

作者：

Cao, Bing ^{[1
,2
]}

Zhou, Xiaoyan ^{[2
,3
]}

Ji, Dongmei ^{[1
,2
]}

Cao, Junning ^{[1
,2
]}

Guo, Ye ^{[1
,2
]}

Zhang, Qunling ^{[1
,2
]}

Wu, Xianghua ^{[1
,2
]}

Li, Junmin ^{[4
]}

Wang, Jianmin ^{[5
]}

Chen, Fangyuan ^{[4
]}

Wang, Chun ^{[6
]}

Zou, Shanhua ^{[7
]}

Hong, Xiaonan ^{[1
,2
]}

机构：

[1] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China

[3] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[4] Shanghai Jiao Tong Univ, Dept Hematol, Ruijin Hosp, Shanghai 200030, Peoples R China

[5] Second Mil Med Univ, Dept Hematol, Changhai Hosp, Shanghai, Peoples R China

[6] Shanghai Jiao Tong Univ, Dept Hematol, Peoples Hosp 1, Shanghai 200030, Peoples R China

[7] Fudan Univ, Dept Hematol, Zhongshan Hosp, Shanghai 200032, Peoples R China

来源：

ONCOLOGY LETTERS | 2012年 / 4卷 / 03期

关键词：

central nervous system; diffuse large B-cell lymphoma; rituximab; ANTI-CD20 ANTIBODY RITUXIMAB; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; CHOP CHEMOTHERAPY; CNS LYMPHOMA; RISK-FACTORS; RICOVER-60; RELAPSE;

D O I：

10.3892/ol.2012.755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy, in combination with rituximab (R-CHOP-like), improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We aimed to investigate the impact of rituximab on central nervous system (CNS) disease in adult patients. We studied 315 patients (aged 18-60 years old) from six hospitals between July 2003 and May 2008. All patients received CHOP-like (n=165) or R-CHOP-like (n=150) regimen every 3 weeks. With a median follow-up of 3.69 years, 10 patients (3.17%) developed CNS disease. The cumulative risk of CNS occurrence was not significantly different between the two treatment groups (P=0.871). We conclude that the addition of rituximab did not reduce the risk of CNS disease in adult patients with DLBCL.

引用

页码：541 / 545

页数：5

共 50 条

[11] Rituximab and chemotherapy in diffuse large B-cell lymphoma [J].

Sonet, Anne ;

Bosly, Andre .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) :719-726

[12] Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B-cell lymphoma [J].

Law, Man Fai ;

Chan, Hay Nun ;

Lai, Ho Kei ;

Ha, Chung Yin ;

Ng, Celia ;

Yeung, Yiu Ming ;

Yip, Sze Fai .

MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) :747-752

[13] Genomic risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma [J].

Jiang, Shiyu ;

Zhang, Qunling ;

Jin, Jia ;

Zhang, Wenhao .

BLOOD RESEARCH, 2025, 60 (01)

[14] Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome [J].

Rozman, Samo ;

Grabnar, Iztok ;

Novakovic, Srdjan ;

Mrhar, Ales ;

Novakovic, Barbara Jezersek .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (08) :1782-1790

[15] Diffuse large B-cell lymphoma with contemporary involvement of central and peripheral nervous system: A case report and literature review [J].

Tang, Chuwen ;

Jiang, Peng ;

Tang, Jinhui ;

Liao, Jinli ;

Zeng, Qingli .

HELIYON, 2024, 10 (07)

[16] Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma [J].

Seok Jin Kim ;

Sung Yong Oh ;

Jin Seok Kim ;

Hawk Kim ;

Gyeong-Won Lee ;

Jong Ho Won ;

Ho Jin Shin ;

Deok Hwan Yang ;

Chul Won Choi ;

Jinny Park ;

Won Seog Kim ;

Cheolwon Suh .

Annals of Hematology, 2011, 90 :539-546

[17] Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors [J].

Roschewski, Mark ;

Dunleavy, Kieron .

LEUKEMIA & LYMPHOMA, 2015, 56 (06) :1583-1584

[18] Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial [J].

Gleeson, M. ;

Counsell, N. ;

Cunningham, D. ;

Chadwick, N. ;

Lawrie, A. ;

Hawkes, E. A. ;

McMillan, A. ;

Ardeshna, K. M. ;

Jack, A. ;

Smith, P. ;

Mouncey, P. ;

Pocock, C. ;

Radford, J. A. ;

Davies, J. ;

Turner, D. ;

Kruger, A. ;

Johnson, P. ;

Gambell, J. ;

Linch, D. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2511-2516

[19] Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement [J].

Lee, Min-Young ;

Kim, Hae Su ;

Lee, Ji Yun ;

Lim, Sung Hee ;

Kang, Eun Suk ;

Ko, Young Hyeh ;

Kim, Seok Jin ;

Kim, Won Seog .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (06) :678-688

[20] Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era? [J].

Cheah, Chan Y. ;

Seymour, John F. .

LEUKEMIA & LYMPHOMA, 2014, 55 (03) :471-473

← 1 2 3 4 5 →